Fifth Affiliated Hospital, Sun Yat-sen University
Clinical trials sponsored by Fifth Affiliated Hospital, Sun Yat-sen University, explained in plain language.
-
Phase ib clinical study of toripalimab combined with gemcitabine and cisplatin neoadjuvant chemotherapy in patients with resectable locally advanced head and neck squamous cell carcinoma
OngoingHead and Neck Squamous Cell Carcinoma (HNSCC) is the most common malignant tumor of the head and neck, accounting for 90% of head and neck malignancies, and 16% to 40% of systemic malignancies. There are 60,000 new cases reported annually worldwide, and the incidence and mortalit…
Phase 1 • Sponsor: Fifth Affiliated Hospital, Sun Yat-Sen University
Last updated Sep 09, 2026 16:00 UTC
-
Neoadjuvant low-dose radiotherapy, tislelizumab, combined with albumin-bound paclitaxel and cisplatin in resectable locally advanced head and neck squamous cell carcinoma (NeoRTPC02): an open label, single-arm, phase II clinical trial
OngoingThis is an open-label, single-arm, phase II clinical trial to explore the efficacy and safety of neoadjuvant low-dose radiotherapy combined with chemoimmunotherapy in resectable locally advanced head and neck squamous cell carcinoma. The eligible patients are scheduled to adminis…
Phase 2 • Sponsor: Fifth Affiliated Hospital, Sun Yat-Sen University
Last updated Sep 09, 2026 16:00 UTC